Medindia

X

First head-to-head trials of once weekly Fosamax and Actonel therapies

by Medindia Content Team on  February 26, 2003 at 3:38 PM Drug News   - G J E 4
First head-to-head trials of once weekly Fosamax and Actonel therapies
The drug major Merck has launched the first two head-to-head clinical trials that compare the efficacy and tolerability of Fosamax (alendronate) once weekly 70mg and Actonel (risedronate) once-weekly 35mg. Fosamax and Actonel, both bisphosphonates indicated for the treatment of osteoporosis in post menopausal women are co-marketed by Aventis and Procter & Gamble through the Alliance for Better Bone Health. The trial called FACTs(Fosamax Actonel Comparison Trials), is being sponsored by Merck as a US-based study, as well as an international study, each of which will examine approximately 800 post menopausal women with osteoporosis(defined by a bone mineral density (BMD) T-score of <=-2). The participants will be randomized in a one-to-one blinded fashion to either alendronate 70mg once weekly or risedronate 35mg once weekly. The trials will then evaluate and compare the effectiveness and tolerability of the 2 agents during 12 months of treatment in the post menopausal women with osteoporosis.

Advertisement
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All